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Abstract
The proposed layered and component based 
software architectural style enables data sharing and 
accessibility of computational software components 
across Biomedical Science problem domains. It also 
opens the door to translational informatics, which 
bridges the gap between knowledge, generated in 
biomedical science, and clinical practices. Software 
applications created from the proposed software
architectural style, are able to support continuous drug 
repurposing.  They exploit the semantic, which exists, 
and is available across biomedical problem domains, 
between drug chemical compounds, their biological 
targets, particularly unintentional targets and drug 
therapeutic effects. The excerpt from the proposed 
software architecture has already been deployed in a 
computationally light-weight software application, 
which manages drug repurposing through reasoning 
upon the available semantic.  However a full scale 
implementation and full deployment of the software 
architecture, plus data sharing across the spectrum of 
biomedical research and disciplines, would require 
some changes in the way therapeutic drugs are 
discovered, tested and approved.
1. Introduction 
Drug repurposing has been in the focus of drug 
development research for almost 2 decades [1] and it is 
recognized as an important part of new drug 
development processes with significant business, 
technical and scientific challenges and strategies [2].  
Reinvestigations of existing, i.e. approved drugs, from 
various perspectives, including academic, existed in the 
literature almost 10 years ago [3,4], and drug-disease 
relationships, for discovering novel uses of drugs [5] 
have been exploited for triggering research on 
computational drug repositioning [6] and its prediction 
in complex diseases [7]. It is interesting that almost 10 
years ago a database for network-based drug 
repositioning was developed and in 2013 an initiative to 
start open source approaches for the repurposing of 
existing and failed candidate drugs was proposed in [9].  
At the same time we had one of the first attempts to use 
machine learning for drug repurposing [10], and shortly 
afterwards interest in applying drug repositioning for 
discovering cancer drugs took off [11,12].  In the last 5 
years, a variety of publications, which address new 
challenges in drug repurposing, started appearing [13]. 
Some of them paid attention to the barriers in the 
process of drug discoveries, such as clinical trials, where 
their costs may adversely affect drug development [14].  
Updated and modernized aspects of drug repositioning 
were urgently needed [15,16,17] and in the last 2 years 
we find publications in which trends, resources, 
repositioning approaches and challenges have been 
debated again [18-21].  Computational drug repurposing 
has started [22], their validation strategies have been 
reviewed [23] and finally there is an initiative to look at 
various tools which could accelerate the drug discovery 
process [24,25].  In this year, 2020, we still find new 
publications which talk about challenges and 
opportunities with drug repurposing [26,27], but the 
appearance of the covid-19 pandemic, brought into
daylight all existing ideas on drug repurposing, aiming 
to answer the demand for finding treatment for 
coronavirus [28-33].
This rather long introduction to the world of drug 
repurposing indicates that we have two problems here.  
a) However we wish to believe that experimental and 
computational methods, for supporting drug 
repositioning, have been defined and exercised in 
the last 2 decades, obviously there is no universal 
and known computational method for supporting 
the process and there is no comprehensive drug 
repositioning strategy.
b) The process of drug discoveries and repositioning 
is far from being trivial, but it is likely that it faces
similar obstacles found in translational informatics 
[34-36].  Scientific discoveries, data, and 
information, available from experiments and 





research in biomedical science do not necessarily 
reach many sub-disciplines across biomedicine, 
pharmaceutical science and clinical practice.  
Sharing of data and scientific discoveries is 
essential for the journey forward and there is no 
evidence that it is happening at present (in 2020). 
It is very difficult to address a) and b) above.  
However, there is something interesting discovered
in all these publications from 2004 onwards.  
Computer scientists are rarely found in the teams 
who have led research on drug repurposing.  Any 
novel solution in drug repurposing would have 
some kind of computations at its core, and would 
require the expertise of computer scientists to 
guarantee generic and deployable solutions.  This 
means that now, in 2020, when software 
technologies and modern computational 
environments have penetrated almost every aspect 
of our lives, it would be unreasonable to keep 
computer science away from research tables and 
debates on unresolved challenges we still have in 
drug repurposing.  The issue of data sharing, as 
described in b) above can be addressed and resolved
from computer science and software engineering 
perspectives and consequently, if we exercise a 
small shift in thinking, we might be in a position to 
influence existing or find new pathways towards 
research solutions for problems described in a).
The authors’ interest in drug repurposing, 
translational informatics and knowledge sharing in 
biomedicine is not new [37,38,39].  However, the 
research was mainly focused on computational models 
which could bring solutions to problems in biomedical 
informatics, through the manipulation of semantics
stored in such environments.  What is currently needed 
is to collate all proposed computations into a conceptual 
software architectural model, which can show exactly 
how information and data are possible to share in the 
biomedical field and relevant computations built across 
shared data.  These conceptual software architectures 
are applicable in many biomedical problem domains 
[40] and it is just a small step forward to apply them in 
drug repositioning.
This paper proposes a generic, layered and 
component based software architectural style [41,42] 
for creating software applications which could initiate 
addressing a) and b) above.  However, the most 
important role of the software architecture (SA) is to 
focus on sharing of data and knowledge across wider 
problem domains in biomedicine and pharmacology, 
and reusing existing computational models, with their 
data repositories for enabling more efficient discoveries 
of data for drug repurposing.  A working prototype from
[43] proves that there are still opportunities to create 
new computations, which would find a way towards 
drug repurposing. This is particularly true if we employ 
software technologies which could interpret the 
meaning of biomedical data in data-sharing, and secure 
reasoning upon its semantic, for the purpose of finding 
relevant semantic in data which could take us toward 
drug repurposing.  Therefore Semantic Web 
Technologies (SWT) [44,45] and their languages, OWL 
and SWRL [46,47] could still be used for retrieving 
existing knowledge in formal medical and biomedical 
ontologies.  The SWT can also be used for reasoning 
upon SWRL enabled OWL ontologies, in order to create 
new computations which would be specific for drug 
repurposing, as illustrated in [43].
Finally, the proposed SA should not be interpreted 
as another attempt to create a new platform or 
framework under which we can create a miracle solution 
for drug repurposing.  It should be the opposite: a new 
light-weight software application, built according to the 
architectural style, easily deployable and not creating
enormous computational burdens on anyone who 
wishes to run such computations.  Obviously, the issue 
of data sharing is essential and could trigger further 
thinking in the manipulation of data from different 
sources or created by different parties, which might not 
be directly involved in drug repurposing.  However, 
these are the questions which could be answered by 
corporations and laboratories which generate 
biomedical data and would depend on their readiness to 
contribute towards achieving a joint goal by sharing 
them.  Consequently, this research can not answer such 
questions, but could prove that the proposed SA is 
feasible, and can be deployed if data sharing culture is 
in place.
The paper is organized as follows. Section 2 
overviews related work in which we look at specific 
computational solutions, using the SWT for drug-
repurposing. Section 3 elaborates on the proposed SA 
for addressing the problem and in Section 4 we illustrate 
the proposal and in section 5 give a generic ontological 
model which would infer drug repositioning according 
to the semantic relationships between drugs and their 
(un)intended targets.  We conclude in section 6.
2. Related Work
At the time of writing the paper there were no 
publications which propose a software architectural 
model for long term solutions in drug repurposing, 
which would include data sharing and reusability of 
existing computations.  In this section, a review of 
papers which come close to the excerpts from this 
proposal are outlined.  Attention is also paid to 
computational solutions, which use reasoning, SWT and 
formal ontologies to aid the drug repurposing process.  
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There is one publication, which helps in promoting 
the feasibility of our proposal and, at the same time, 
influences the implementation of the prototype from 
[43]. The idea of exploiting the drug-target 
identification, using side-effect similarity, as described 
in [48], may have an impact on the process of 
discovering new purposes of existing drugs.  It enables 
focusing on phenotypic side-effect similarities in order 
to infer if two drugs share the same target.  The power 
of side effects could add more semantics to any OWL 
model used for knowledge presentation and strengthen 
the reasoning process needed in drug re-positioning.  
However, this is not the only way of reasoning/inference 
for drug repositioning, but it remains a powerful 
mechanism for computational analysis of the semantic 
of drugs and their unintentional biological targets.  If 
these ideas could be fully converted into a 
computational model as in [43] then there is an 
opportunity to find more overlapping semantic between 
drugs and their intended and non-intended biological 
targets.
A new wave of innovations, which use SWT tools 
for drug discoveries from [49] would fit within the main 
structure of the proposed SA model.  However, none of 
the papers referenced in [49] come close to the proposed
SWRL enabled OWL model from [43] for one 
important reason.  Our proposal includes building a 
software engineering solution with a software
application in mind, and creating a computational model 
based on SWRL enabled reasoning.  This is rather 
different to the traditional use of ontologies for semantic 
annotations in drug discoveries.
The deployment of learning and mining 
technologies for drug re-positioning was initiated in this 
decade [50,10, 7] because of an excessive amount of 
data and information we have been generating in 
Biomedical science and research.  Consequently, we 
talk about databases for network based drug 
repositioning [8], the changed landscape of academic 
drug discoveries [15] and pathway analysis based on 
Public Database mining as in [13], as mentioned in the 
introduction.  However, this we should not pursue a 
uniform computational model for this problem domain.  
It is sufficient that all current results of biomedical 
research, including predicting drug side effects from 
Drug – Target relationships as in explained [51] and 
relating proteins to drug side effects as described in [52], 
and finding their space in computational models from 
the proposed SA, which was emphasized in [43].  It goes 
without saying that work from [53-55] would find its 
space in the proposed SA model.
It was mentioned in the Introduction that a very 
rich, published literature, focusing on drug 
repositioning, has been sourced from papers which do 
not involve enough (if any?) computer scientists. 
Therefore all their work remains in the field of 
knowledge building and classifications.  This is far away 
from any universal and long term solutions which could 
enable a constant process of drug repositioning.  
Hopefully, this proposal might change the picture of the 
this problem domain landscape.
3. The Proposal: SA Model
The proposed SA model is in Figure 1.  As a layered 
and component based architectural style it has specific 
characteristics which resemble the MVC pattern, typical 
for software modelling, where separation of concerns is 
essential.  For readers not familiar with principles of 
software architectures and patterns, it is important to pay 
attention to layering of software components which 
secure the separation of user interfaces, computational 
components and software components which house data 
and data repositories, in general. Therefore each layer of 
the SA model in Figure 1 contains software components 
of the same type. 
Figure 1: The Proposed Software Architecture for FRD
(Finding Repurposed Drug)
The computational layer is very important because 
it can house a variety of computational models and thus 
the SA ensures that these computations are fed by 
relevant data repositories.  Very often in computational 
components we recognize a variety of functionalities 
which are supposed to be delivered by software 
applications generated from the SA.  Therefore the Data 
layer must contain all possible data repositories which 
might be needed by any of the computational 
components from the middle layer.
One of the most important aspects of software 
component layering is that its deployment is managed 
by Integrated Development Environments (IDE) and 
thus these tools secure communication between layers.  
Also the proposal strictly follows an architectural style 
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which allows communication between software 
components by utilizing the role of each layer.  The 
separation of concerns allows adding more software 
components in each layer if needed. Therefore more 
computations are welcome, as long as we have data 
repositories available for running such computations.  
Distribution of these software components is feasible 
and thus they may not in reality always belong to the 
same software applications.  In other words data 
repositories may be shared across various computations
as long as there is agreement between different parties, 
who are the owners of these data repositions that data 
could be shared.
In summary, data sharing across computations is 
not feasible i) if the rules of software component 
layering are not followed and ii) if we do not keep 
separation of concerns in mind.  Bearing in mind that 
today, we often compute with data which do not 
originate in our computational environment, then it is of 
the upmost importance that the SA defines which 
computations will be dependent on which data 
repository(ies).
3.1. Description of Computational Software 
Components
The SA from Figure 1 is generic, but software 
components within it are technology specific.  When 
defining and proposing any SA style, we must ensure 
that it is deployable within an IDE.  In this particular 
case, NetBeans IDE and J2E technology are used for the 
deployment of the proposal and components carry 
technology specific tags.  Therefore the computational 
components in Figure 1 are deployed as either servlets, 
or java beans, which in turn means that we can include 
Java level of programming, SQL types of code together 
with potential database definitions and retrievals plus 
any other type of computing we may need, within the 
middle layer of Figure 1.  OWL-API is a software 
component which contains an API in order to take us 
towards software components deployed with different 
technologies: SWT and its languages. In these cases, 
computations within SWRL enabled OWL ontologies 
happen with a rule language, which performs reasoning
upon data stored in OWL concepts.  This means that 
reasoning is performed using an unusual, but often used 
data repository denoted in Figure 1 as green and yellow 
circles (left and rightmost parts of the data layer in 
Figure 1).  SWT is a different technology compared to 
our traditional database management and programming 
with procedural languages and thus this computational 
part has 2 pathways: either retrieval of data through 
OWL-API using SPARQL or reasoning upon data using 
SWRL.  Obviously data stored in OWL ontologies could 
be accessed through OWL-API only, but these plug-ins 
are available across many IDE and work very well 
within Android operating environments.  In summary, a 
green bidirectional arrow denotes initiation of SPARQL 
retrievals or reasoning with SWRL, plus any other type 
of defining essential OWL concepts or defining SWRL 
rules in advance. The yellow bidirectional arrow means 
that the model supports retrievals with SPARQL and 
definition of OWL classes and their semantics.  A one-
directional yellow arrow supports SPARQL retrievals 
only. Blue arrows refer to database definitions, 
retrievals and updates.
Red arrows denote access to unstructured data and
data sets, often used for processing big data and running
various types of predictions, such as machine learning 
classifications (to mention just the most popular way of 
performing predictive inference in modern computing).  
These software components, reserved for ML 
algorithms, are tagged as servlets, but they could have 
their own API which could take the computations 
towards software tools to run predictions upon available 
data sets.  This part of the SA model open doors to 
running predictions with ML algorithms, together with 
SQL retrievals from traditional transactional processing 
and reasoning upon OWL concepts, all under one 
umbrella of software applications which uses a variety
of software technologies. 
3.2. Description of Functionalities Defined in 
the SA
Figure 1 introduces three different types of 
functionalities.  They are visible through its vertical 
lines, which cross the layers of the SA. 
On the right part of the figure, we define FRD 
which stands for Finding Repositioning for a Drug.  A 
possible reposition is a result of reasoning upon SWRL 
enabled OWL ontology, denoted in the green circle 
which is a software component containing OWL 
concepts and reasoning rules associated to them.  
However the reasoning depends on the OWL model, and 
the OWL model in turn depends on the knowledge 
extracted from Biomedical data repositories.  They can 
range from formal ontologies (the left bottom part of the 
SA) and various unstructured (e.g. data sets) and 
structured repositories available across biomedical 
research.  Therefore, Figure 1 signals that we have to 
have a structured repository for defining drug 
repurposing criteria, which can be generated for a 
particular drug after retrieving the existing formalized 
knowledge and data from biomedical experiments. The 
SQL retrievals through FRD java class brings semantics
for creating ontological concepts and reasoning rules in 
FRD computational ontologies.
The middle part of Figure 1 accommodates the 
functionality of Defining Repurposing Criteria (DRC).  
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This computation is likely to operate in SQL like 
environments where various database retrievals from 
biomedicine could bring enough knowledge to define 
criteria.  The data component of this functionality is 
represented by only one database symbol, but in reality, 
there should be numerous structured repositories which 
can contain semantic relevant for defining the criteria.  
Whether these repositories should belong to the middle 
functional column (DRC) or to the left one, could be 
debated, but the layered SA could accommodate any 
changes we may have when associating computations
from the middle layer with data repositories.
The left part of Figure 1 is likely to be found outside 
the software applications which exactly compute drug 
repositioning (right part of Figure 1).   This means that 
the world of biomedical knowledge is responsible for 
creating and storing their knowledge. It may contain its 
own computations in order to process biomedical data 
as part of their own research; it may run ML algorithms 
for the purpose of running biomedical experiments and 
research and may create formal ontologies (yellow oval 
symbol) for accumulating biomedical knowledge.  
DUBS stands for Defining and Updating Biomedical 
Sources, and thus it is likely that the DUBS.Sservelet 
will operate outside the environment where FRD 
computes.  However, their “connection” is in sharing of 
data (possibilities are a yellow one-directional line and 
red arrows).
4. Illustration of the Proposed SA
Figure 2 denotes which part of the proposed SA was 
deployed and which data repositories we used in the 
deployment, for creating a software application.  The 
software application is circled with a green broken line.
The FRD Servlet and Java classes were 
programmed, but we did not have the Repurposing 
Criteria Data repository explicitly available and thus had 
to create it.  The deployment of the FRD functionality 
has been published in [43] with ontological concept and 
reasoning upon them. Figures 3 and 4 show its OWL 
model and the reasoning process, both taken from [43]. 
The most important part was the repurposing criteria, 
which was deployed as OWL constraints but extracted 
from the literature, i.e. published papers because there is 
no formal source which stores semantics relevant to 
drug repurposing. 
On this occasion, we looked at side effects of drugs 
approved for a specific target (gene, biological 




This was easy to collect and use as our repurposing 
criteria, because some of the publications available 
online do follow predication semantics [56, 57] in which 
relationships between drugs and their targets can be 
presented as the subject-predicate-object triples 
[58,59].  Considering that OWL concepts are based on 
RDF triples and they do support semantically subject-
predicate-object notion, it was extremely easy to create 
OWL concepts, find their constraints and write SWRL 
rules for the example above.  
Figure 2 Excerpts from the Implementation
Fig. 3 Ontological Classes for DRUG Ontology [43]
The reasoning rules have “found” that 
“Amantadine could be repositioned for Parkinson’s 
disease”. 
It is important to note that the implemented model 
and reasoning from [43] proved the concept: we could 
infer drug repositioning through reasoning.  However, 
our criteria for repurposing is one of many possibilities 
to represent a complex relationship between drugs and 
their biological targets, which can be formalized though 
OWL concepts and used in reasoning.
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5. Formal Ontological Model for FRD 
Computations
The OWL model from Figure 3, is repurposing 
criteria specific in terms of using side effects for finding 
possibilities of drug repurposing.  However, this paper 
offers a generic OWL model, for any other type of 
repurposing criteria.  For example, it could use semantic 
relationship between drugs intentional and non-
international targets.  Figure 5 shows a generic OWL 
model with the reasoning processes interwoven.  This is 
probably one of many possibilities of using description 
logic in managing overlapping semantics between OWL 
terms for drug repurposing, and thus more debate is 
needed to find out which repurposing criteria could be 
seen as the most generic.
Figure 4: The Reasoning Process for Inferring Drug 
Repurposing (with OWL Classes and Constraints) [43]
The generic OWL model with the reasoning 
process in Figure 5 is self-explanatory.  Drug Drdugi is 
described through its intentional {ti,1, ti,2,, … ti,n} and 
unintentional targets: {ti,n+1, ti,n+2,, … ti,m}, and the same 
applies to drug Drugj with {tj,1, tj,2,, … tj,k}, and {tj,k+1, 
tj,k+2,, … tj,l.} where i,j are elements of N.  The most 
powerful part of the model is very difficult to draw and 
requires a detailed table with object properties defined 
between the domain and range classes, but the bi-
directional black arrow between Drugi and Drugj 
classes is the place where we define object properties on 
the diagram.  They may contain all possible semantic, 
including the overlapping semantic between Drugi and 
Drugj, plus the set of targets:  {ti,1, ti,2,, … ti,n}, {ti,n+1, 
ti,n+2,, … ti,m},}, {tj,1, tj,2,, … tj,k}} {tj,k+1, tj,k+2,, … tj,l., }. 
What is important to read from the diagram is that the 
result of reasoning is not a particular new drug: it is an 
object property between existing drug Dj and Diseasei, 
which did not exist before (red arrow shows where the 
reasoning happens and what is being inferred).  From 
this perspective, the model does not depart from the 
implementation in [43], where its inference is in the 
form of the object properties. This means that the 
individual of Di class (a particular DRUG) has been 
repurposed to be relevant for Diseases.   Therefore the 
power of the model is in our way of describing drugs 
through their targets.  Targets, from the computer 
science point of view, can really be ANYTHING which 
contains the semantic relevant to the drug and thus the 
model also allow predicate semantic to be used as much 
as possible and pay more attention to un-intentional 
targets, which may hide drug effects not visible, or 
known or even not reported.  For readers interesting in 
the applicability of generic OWL models, as in Figure 5
in computational reasoning, when OWL model and 
SWRL reasoning become a core part of the main 
computational model, we suggest reading the authors’ 
earlier publications. 
Figure 5: Generic OWL Model for continues Drug 
Repurposing 
6. Conclusions
This paper touches the tip of the iceberg of the 
problems we face in the field of sharing and
disseminating data and knowledge across Biomedical 
science and related disciplines [59] and the issue of drug 
repositioning is not an exception.  Since the early 2000s
we have not conquered the drug repositioning problem, 
in spite of reading some very interesting proposals and 
ideas. To the eyes of computer scientists, the lack of 
their involvement in the problem solving process is a 
problem. Also, the absence of a generic SA model which 
must allow data sharing across disciplines which should 
enable sharing of data and knowledge, can not take us 
forward in drug repositioning.  The proposal shows how 
feasible and efficient some software solutions in this 
field could be.  The issues of heterogeneity and 
interoperability in this field, privacy of medical data and 
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data in general are very easy to resolve and the model
we propose, together with its separation of concern can 
guarantee almost all of them.  These types of SA have 
been around for almost 2 decades and are probably one 
of the most successful ways of constructing software in 
modern computing.
This work would be primarily of interest to 
pharmaceuticals and research in new drug development.   
However, there is something else here which should 
attract the attention of any lab and research group in 
Biomedical Science or Pharmacology.  Their research 
results sometimes remain completely buried in peer-
reviewed publications, which are being generated at 
enormous speed, as we write this.  It has become 
impossible to have any overall picture of research 
progress in Biomedical science and interesting details of 
research results sometimes never get read or evaluated.  
There should be a joint interest in sharing data and 
information across all these disciplines through software 
applications and the message from computer scientists 
is that this is very feasible and not difficult to design and 
implement.
10. Reference
[1]. Ashburn, T. T.&Thor, K. B., "Drug Repositioning, 
identifying and developing new uses for existing drugs” 
Nature reviews Drug discovery, 2004, 3(8) pp.673.
[2]. Barratt MJ, Frail DE.,”Drug Repositioning Bringing 
New Life to Shelved Assets and Existing Drugs”. 2012,
Hoboken, United States: John Wiley & Sons.
[3]. Oprea, T. I., Bauman, J. E., Bologa, C. G., Buranda, T., 
Chigaev, A., Edwards, B. S., Jarvik, J. W., Gresham, H. 
D., Haynes, M. K.& Hjelle, B., "Drug repurposing from 
an academic perspective," Drug Discovery Today: 
Therapeutic Strategies, 2011, 8(3-4). pp.61-69.
[4]. Padhy, B.M.; Gupta, Y.K. Drug repositioning:  Re-
investigating existing drugs for new therapeutic 
indications. J. Postgrad. Med. 2011, 57, 153–160.
[5]. Chiang, A P, and A J Butte. “Systematic evaluation of 
drug-disease relationships to identify leads for novel drug 
uses.” Clinical pharmacology and therapeutics vol. 86,5 
(2009): 507-10.
[6]. Dudley, J. T., Deshpande, T.& Butte, A. J., "Exploiting 
drug–disease relationships for computational drug 
repositioning," Briefings in bioinformatics, 2011, 12(4). 
pp.303-311.
[7]. Yang., J., Li, Z., Fan, X., Cheng, Y. "Drug-disease 
association and drug-repositioning prediction in complex 
diseases using casual inference probabilistic matrix 
factorization", in Chemical Information and Modelling, 
2014, Vol 54, pp. 2562-2569
[8]. von Eichborn, J., Murgueitio, M.S., Dunkel, M., 
Koerner, S., Bourne, P.E., Preissner, R. 
"PROMISCUOUS: a database for network-based drug-
repositioning", in Nucleic Acid Research, 2014, Volume 
39, Database Issue
[9].Allarakhia M. “Open-source approaches for the 
repurposing of existing or failed candidate drugs: learning 
from and applying the lessons across diseases”. Drug Des 
Devel Ther. 2013; 7:753-766.
[10]. Napolitano, F., Zhao, Y., Moreira, V. M., Tagliaferri, 
R., Kere, J., D’Amato, M.& Greco, D. "Drug 
repositioning: a machine-learning approach through data 
integration," Journal of cheminformatics, 2013. 5(1). 
pp.30.
[11]. Shim, J. S.& Liu, J. O., "Recent advances in drug 
Repurposing/repositioning for the discovery of new 
anticancer drugs," International journal of biological 
sciences, 2014. 10(7). pp.654. 
[12]. Shah ET, Upadhyaya A, Philp LK. “Repositioning 
"old" drugs for new causes: identifying new inhibitors of 
prostate cancer cell migration and invasion”. Clin Exp 
Metastasis. 2016; 33:385-99.
[13]. Pan, Y., Cheng, T., Wang, Y., Btyant, S.H. “Pathway 
Analysis for Drug Repositioning Based on Public 
Database Mining”, in Chemical Information and 
modelling, Vol 54, pp pp.407-418. 
[14]. Sertkaya A, Birkenbach A, Berlind A, Eyraud J. 
“Examination of clinical trial costs and barriers for drug 
development”. US Department of health and human 
services, office of the assistant secretary for planning and 
evaluation report. 2014; 1:1-92.
[15]. Oprea TI, Overington JP. “Computational and Practical 
Aspects of Drug Repositioning”. Assay Drug Dev 
Technol. 2015; 13:299-306.
[16]. Langedijk J, Mantel-Teeuwisse AK, Slijkerman DS, 
Schutjens MH. “Drug repositioning and repurposing: 
terminology and definitions in literature”. Drug Discov 
Today. 2015; 20(8):1027-1034.
[17]. Li, J.; Zheng, S.; Chen, B.; Butte, A.J.; Swamidass, S.J.; 
Lu, Z. “A survey of current trends in computational drug 
repositioning”. Brief. Bioinformatics. 2016, 17, 2–12.
[18]. Xue, H., Li, J., Xie, H.& Wang, Y. "Review of drug 
repositioning approaches and resources," International 
journal of biological sciences, 2018. 14(10). pp.1232.
[19]. Yella JK, Yaddanapudi S, Wang Y, Jegga AG. 
“Changing Trends in Computational Drug 
Repositioning”. Pharmaceuticals (Basel, Switzerland). 
2018 Jun;11(2). DOI: 10.3390/ph11020057.
[20]. Oliveira EAM, Lang KL. “Drug Repositioning: 
Concept, Classification, Methodology, and Importance in 
are/Orphans and Neglected Diseases”. Journal of App 
Pharm Sci, 2018; 8(08): 157-165.
[21]. Pushpakom S, Iorio F, Eyers PA, et al. Drug 
repurposing: progress, challenges and 
recommendations. Nat Rev Drug Discov. 2019;18(1):41-
58. doi:10.1038/nrd.2018.168
[22]. Karaman B, Sippl W. “Computational Drug 
Repurposing: Current Trends”. Curr Med Chem. 
2019;26(28):5389-5409.
Page 3719
[23]. Brown AS, Patel CJ. “A review of validation strategies 
for computational drug repositioning”. Brief Bioinform. 
2018;19(1):174-177. doi:10.1093/bib/bbw110
[24]. Park K. “A review of computational drug 
repurposing”. Transl Clin Pharmacol. 2019;27(2):59-63. 
doi:10.12793/tcp.2019.27.2.59
[25]. Parvathaneni V, Kulkarni NS, Muth A, Gupta V. 
“Drug repurposing: a promising tool to accelerate the 
drug discovery process”. Drug Discov Today. 
2019;24(10):2076-2085. doi: 
10.1016/j.drudis.2019.06.014
[26]. Alan Talevi & Carolina L. Bellera, “Challenges and 
opportunities with drug repurposing: finding strategies to 
find alternative uses of therapeutics”, Expert Opinion on 
Drug Discovery, 2020, 15:4, 397-401.
[27]. Palve V, Liao Y, Remsing Rix LL, Rix U. “Turning 
liabilities into opportunities: Off-target based drug 
repurposing in cancer [published online ahead of print, 
2020 Feb 7]. Semin Cancer Biol. 2020; S1044-579X 
(20)30036-5. doi: 10.1016/j.semcancer.2020.02.003
[28]. Rameshrad M, Ghafoori M, Mohammadpour AH, 
Nayeri MJD, Hosseinzadeh H. “A comprehensive review 
on drug repositioning against coronavirus disease 2019 
(COVID19)”. Naunyn Schmedebergs Arch Pharmacol. 
2020;393(7):1137-1152.   doi:10.1007/s00210-020-
01901-6
[29]. Cliberto, G., Mancini, R., & Paggi, M. G. (2020). 
“Drug repurposing against COVID-19: focus on 
anticancer agents”. Journal of experimental & clinical 
cancer research :2020. CR, 39(1), 86. 
https://doi.org/10.1186/s13046-020-01590-2
[30]. Martin, J. H., & Bowden, N. A. (2020). “Drug 
repurposing in the era of COVID-19: a call for leadership 
and government investment”. The Medical journal of 
Australia, 212(10), 450–452.e1. 
https://doi.org/10.5694/mja2.50603
[31]. Pawar A. Y. “Combating devastating COVID-19 by 
drug repurposing”. International journal of antimicrobial 
agents, 105984. 2020. Advance online publication at 
https://doi.org/10.1016/j.ijantimicag.2020.105984
[32]. Senanayake S. L. “Drug repurposing strategies for 
COVID-19”. Future Drug Discovery, 0(0), fdd-2020-
0010. https://doi.org10.4155/fdd-2020-0010
[33]. Serafin, M. B., Bottega, A., Foletto, V. S. da Rosa, T. 
F., Hörner, A., & Hörner, R. “Drug repositioning is an 
alternative for the treatment of coronavirus COVID-
19”. 2020. International journal of antimicrobial 
agents, 55(6), 105969.
[34] Tsafnat G., Lin F., Choong M.K. (2013) Translational 
Biomedical Informatics. In: Dubitzky W., 
Wolkenhauer O., Cho KH., Yokota H. (eds) 
Encyclopaedia of Systems Biology. Springer, New 
York, NY
[35] Butte AJ. “Translational bioinformatics: coming of 
age”. J Am Med Inform Assoc, 2008. 15(6):709–714, 
Available on-line, M2824v1
[36] Machado, C. M.; Rebholz-Schuhmann, D.; Freitas, A. 
T.; Couto, F. M. “The semantic web in translational 
medicine: current applications and future directions”. 
Briefings Bioinf. 2015, 16, 89.
[37] Tarabi, M., Juric, R. “Software Architectures for Smart 
Applications in the Management of Chronic Diseases: A 
Case Study of Reversibility of Diabetes 2”, In 
Proceedings of the 51st HICSS Conference January 2018.
[38] Almami, I., Almami, E., Juric, R. “ Knowledge 
Dissemination In Biomedical Science: Using Ontological 
Reasoning for the Analyses of Activated Enzymes in 
Various Diseases, In Proceedings of the 21st SDPS 2016 
conference, December 2016 
[39]Juric, R., Almami, E. Almami, I. “Semantic Overlapping 
of OWL Models in Biomedicine”, In Proceedings of the 




[40] Juric, R., Williams, E., Kim, I. “Semantic Overlapping 
in Translational Bioinformatics Applied to the Matching 
between Clinical Trial Eligibility Criteria and Patient 
Needs”, in Proceedings of the 13th International Joint 
Conference on Biomedical Engineering Systems and 
Technologies (BIOSTEC 2020) - Volume 3: 
BIOINFORMATICS, Valletta, Malta, February 24-26, 
2020,
[41]Cervantes, H., Kazman, R. Designing Software 
Architectures: A Practical Approach (SEI Software 
Engineering), Addison Wesley; 01 edition (13 May 2016)
[42] Yonglei Tao, "Component- vs. application-level MVC 
architecture," 32nd Annual Frontiers in Education, 
Boston, MA, USA, 2002, pp. T2G-T2G, doi: 
10.1109/FIE.2002.1157950.
[43] Juric, R, Almami, E. “Proposing Drug Repositioning 
though Semantic Reasoning”, In proceedings of the 24th 
Conference on SDPS 2019, Taichung, Taiwan, June 2019.
[44]. SWT. 2004. Semantic Web Technology SWT Road 
Map, at W3C website https://www.w3.org/2001/10/03-
sww-1/slide7-0.html
[45] Jan Horrocks, Peter.F. Patel-Schneider, Harold Boley, 
Said Tabet, Benjamin Grosof, Mike Dean, “SWRL: A 
Semantic Web Rule Language Combining OWL and 
RuleML”. 2004. National Research Council of Canada, 
Network Inference, and Stanford University. 
http://www.w3.org/Submission/SWRL/
[46]. SWRL: A Semantic Web Rule Language Combining 
OWL and RuleML 2004 [Available from: at 
https://www.w3.org/Submission/SWRL/
[47]. Deborah.l. McGuinness, Frank.V. Harmelen. “OWL, 
Web Ontology Language, The World Wide Web 
Consortium (W3C). 2004. https://www.w3.org/TR/owl-
features/
[48]. Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J. & 
Bork P., (2008), "Drug target identification using side 
effect similarity," Science, 321(5886). pp.263-266.
[49]. Kanza, S., Frey, J.G. “A new Wave of innovation in 
Semantic Web Tools for drug discovery”, in Expert 
Opinion on Drug Discovery, 2014. Vol 14, No 5, pp. 433-
444.
Page 3720
[50]. Andronis, C., Sharma, A., Virvilis, V., Deftereos, S.& 
Persidis, A. "Literature mining, ontologies and 
information visualization for drug repurposing," Briefings 
in bioinformatics, 2011. 12(4). Pp.357-368.
[51]. Perez-Nueno, V.I., Souchet, M., Karaboga,  A. S., 
Ritchie, D. W. “GESSE: Predicting Drug Side Effects 
from Drug–Target Relationships”, Journal of Chemical 
Information and modelling, 2015. Vol, 55, pp. 1804-1823
[52]. Liu, T., Altman, R.B. “Relating Essential Proteins to 
Drug Side-Effects Using Canonical Component Analysis: 
A Structured-Based Approach”, in Journal of Chemical 
Information and modelling, 2015. Vol, 55, pp. 1483-1494.
[53]. Liang, C., Sun, J.& Tao, C. "Semantic Web Ontology 
and Data Integration: a Case Study in Aiding Psychiatric 
Drug Repurposing," Studies in health technology and 
informatics, 2015. 1(216). pp.1051-1051
[54]. Mullen, J. “DReNIn_O A high-level ontology for drug 
repositioning” available at 
https://slideplayer.com/slide/13323615/
[55]. Xu, R.&Wang, Q., "Large-scale extraction of accurate 
drug-disease treatment pairs from biomedical literature 
for drug repurposing," 2013. BMC bioinformatics, 4(1). 
pp.181.
[56] Ahlers, C.B., Fiszman, M., Demner-Fushman, D., Lang, 
F. M.T. Rindflesch, C. «Extracting Semantic Predications 
from Medline”, Citations for Pharmacogenomics, Pacific 
Symposium on Biocomputing 12:209-220(2007).
[57] Kilicoglu H, Shin D, Fiszman M, Rosemblat G, 
Rindflesch TC. “SemMedDB: a PubMed-scale repository 
of biomedical semantic predications”. Bioinformatics 
2012;28:3158–60.
[58] Juric, R., Williams, E., Kim, I. “Semantic Overlapping 
in Translational Bioinformatics Applied to the Matching 
between Clinical Trial Eligibility Criteria and Patient 
Needs”, in Proceedings of the 13th International Joint 
Conference on Biomedical Engineering Systems and 
Technologies (BIOSTEC 2020) - Volume 3: 
BIOINFORMATICS, Valletta, Malta, February 24-26, 
2020, SCITEPRESS 2020, ISBN 978-989-758-398-8
[59] Juric, R. “Adding Value to Translational Informatics 
through the Semantic Management of Drug to Drug 
Interaction”, In Proceedings of the 13th International Joint 
Conference on Biomedical Engineering Systems and 
Technologies (BIOSTEC 2020) - Volume 3: 
BIOINFORMATICS, Valletta, Malta, February 24-26, 
2020, available at SCITEPRESS 2020, ISBN 978-989-
758-398-8
Page 3721
